← Back to all signals
RESEARCH PAPER ANALYSIS

Susceptibility-weighted imaging in patients with Corticobasal Syndrome or Progressive Supranuclear Palsy: distribution of iron deposits reflects clinical symptoms in 4-R tauopathies.

This 3T MRI study shows that frontal cortical T2* hypointensity (likely reflecting iron accumulation/neuroinflammation) is ubiquitous in corticobasal syndrome, rarer in PSP, and its regional distribution correlates with specific motor and language deficits.

PMID41951427
JournalAJNR. American journal of neuroradiology
Publication Date2026-04-08
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

This 3T MRI study shows that frontal cortical T2* hypointensity (likely reflecting iron accumulation/neuroinflammation) is ubiquitous in corticobasal syndrome, rarer in PSP, and its regional distribution correlates with specific motor and language deficits.

WHY IT MATTERS

Research significance

Provides a noninvasive imaging biomarker linking iron/inflammation topography to clinical phenotype in 4‑repeat tauopathies, aiding patient stratification, diagnostic accuracy, and mechanistic or therapeutic targeting of neuroinflammation/iron-related pathology.

ABSTRACT

Source abstract

BACKGROUND AND PURPOSE: Patients with corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP) often show the loss of the "swallow tail sign", which reflects degeneration of dopaminergic neurons and iron accumulation in the substantia nigra pars compacta, and peculiar neuroradiological signs which are, respectively, asymmetrical frontoparietal atrophy and midbrain atrophy. A T2* hypointense rim likely reflecting presence and distribution of neuroinflammation has been recently reported in the frontal cortex of CBS patients. Here we investigated (i) the frequency of conventional radiological signs associated with CBS and PSP and (ii) presence, distribution and frequency of the T2* signal hypointensity in the frontal cortex in CBS and PSP patients. In addition, (iii) we explored possible associations between T2* hypointensity in the frontal cortex and clinical symptoms. MATERIALS AND METHODS: Sixty-two patients were retrospectively included in the study (14 CBS and 48 PSP). Two neuroradiologists inspected the 3T MR datasets and recorded the presence/absence of: asymmetric frontoparietal atrophy, midbrain atrophy, loss of the "swallow tail sign" and T2* hypointensity of the frontal cortex. RESULTS: Asymmetrical frontoparietal atrophy and T2* hypointensity in the frontal cortex were more frequent in CBS patients (p<0.001) whereas midbrain atrophy and the loss of the "swallow tail sign" were so in PSP patients (p<0.001). The T2* signal hypointensity in the frontal cortex was detected in 14 CBS (100%) and five PSP (10%) patients and had three possible patterns of distribution associated with specific symptoms: (A) involvement of the hand knob only (three CBS and no PSP patients) in patients with unilateral ideomotor apraxia; (B) involvement of the primary motor cortex which extended beyond the hand knob (two CBS and five PSP patients); both CBS patients had bilateral ideomotor apraxia; (C) involvement of the primary motor cortex, the superior and/or the middle frontal gyrus (nine CBS and no PSP patients); all but one of these patients had ideomotor limb apraxia and all had speech/language impairment. CONCLUSIONS: The T2* signal hypointensity in the frontal cortex may be an additional radiological sign to be assessed in patients with atypical parkinsonism. Its distribution across the frontal gyri likely reflects clinical symptoms. The pathological assessment of CBS cases would support the robustness of these results.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic